New Delhi, Nov 21 (UNI) Leading pharma firm Ranbaxy Laboratories Ltd (RLL) today said it has received the approval to manufacture and market Tamsulosin Hydrochloride capsules in Canada.
''The capsules, in the strength of 0.4 mg have been approved by Health Canada, Therapeutic Products Directorate (TPD),'' a company statement said.
The capsule is used for treatment of Benign Prostatic Hyperplasia (BPH).
The total market for both generic and branded Tamsulosin Hydrochloride Capsules in Canada is 22 million Canadian dollars.
''The approval will expand Ranbaxy's product portfolio of accessible and affordable generic product offerings,'' said Paul Drake, President, Ranbaxy Pharmaceuticals Canada Inc (RPCI), Canada.
Ranbaxy Pharmaceuticals-Canada Inc (RPCI), based in Ontario, Canada, is a wholly-owned subsidiary of RLL.
RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.